{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:04Z","timestamp":1792804144436,"version":"4.5.0"},"reference-count":39,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The role of circulating tumor DNA (ctDNA) monitoring in predicting treatment response and survival outcomes in early-stage and metastatic solid tumors has shown promising results. The value of early ctDNA dynamics in solid tumors treated with immune checkpoint inhibitors (ICIs) merits further investigation. Our study aims to assess the role of early ctDNA changes, measured 3-4 weeks after initiating ICI therapy, in predicting clinical outcomes in patients with advanced-stage melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      We performed a multi-institutional analysis of real-world data from testing patients with unresectable stage III\/IV melanoma using a personalized, tumor-informed ctDNA assay (Signatera) during the course of treatment with anti\u2013PD-1-based therapy. ctDNA levels were assessed before the start of treatment and at 3-4 weeks before the second treatment dose. The change in ctDNA (decrease\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      increase) between the two points was assessed to evaluate the odds of objective response and disease control and to evaluate the risk of progression-free survival (PFS) and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      One hundred seventeen patients were evaluated. Regression analysis revealed that a decrease in ctDNA was associated with increased odds of disease control (odds ratio [OR], 30.56 [95% CI, 10.64 to 87.84],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) and objective response (OR, 23.54 [95% CI, 8.58 to 64.57],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). Patients with a decrease in ctDNA had an increased PFS (hazard ratio [HR], 0.18 [95% CI, 0.11 to 0.31],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) and OS (HR, 0.28 [95% CI, 0.13 to 0.56],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) probability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>We found that early ctDNA dynamics after only 3-4 weeks of ICI initiation in patients with advanced-stage melanoma appears to be a candidate strategy to predict overall treatment response, risk of progression, and long-term survival. Larger prospective studies are warranted to validate the utility of early ctDNA changes in treatment monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-00254","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:59:20Z","timestamp":1771016360000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":6,"title":["Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-2787","authenticated-orcid":true,"given":"Vincent T.","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, WI"},{"name":"Department of Dermatology, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-8666","authenticated-orcid":true,"given":"Alice Y.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Washington University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6461-5448","authenticated-orcid":true,"given":"Amir","family":"Forati","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin-Madison, Madison WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fauzia","family":"Hollnagel","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin-Madison, Madison WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5069-0945","authenticated-orcid":true,"given":"Janmesh D.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, WI"},{"name":"Department of Dermatology, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Burkey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1932-0338","authenticated-orcid":true,"given":"Alyssa","family":"Steimle","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin-Madison, Madison WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak M.","family":"Sahasrabudhe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3085-4670","authenticated-orcid":true,"given":"Matthew C.","family":"Mannino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-997X","authenticated-orcid":true,"given":"Jennifer L.","family":"Schehr","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-2561","authenticated-orcid":true,"given":"Alexander","family":"Birbrair","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9166-6507","authenticated-orcid":true,"given":"Shuang G.","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Human Oncology, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-8872","authenticated-orcid":true,"given":"Joshua M.","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-7366","authenticated-orcid":true,"given":"Adrienne I.","family":"Victor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041106"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133448"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0168"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2019-0003"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-021-00440-4"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.467"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108613"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1731942"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52923-0"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03254-6"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06225-y"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8618"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","unstructured":"Loupakis F Sharma S Derouazi M et al: Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. JCO Precis Oncol 10.1200\/PO.21.00101","DOI":"10.1200\/PO.21.00101"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae155"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.04.008"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.09.004"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.07.001"},{"key":"e_1_3_8_22_2","unstructured":"Reference deleted"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34716"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0096-5"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5332"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature17038"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719264115"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0557"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.59677"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.08.034"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.873728"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113361"},{"key":"e_1_3_8_33_2","unstructured":"Reference deleted"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030495"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.982983"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.188839"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2022.10.006"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04949-x"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","unstructured":"Jang A Lanka SM Jaeger EB et al: Longitudinal monitoring of circulating tumor DNA to assess the efficacy of immune checkpoint inhibitors in patients with advanced genitourinary malignancies. JCO Precis Oncol 10.1200\/PO.23.00131","DOI":"10.1200\/PO.23.00131"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036269"}],"updated-by":[{"DOI":"10.1200\/po-26-00740","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000}}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:19:37Z","timestamp":1784204377000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1200\/PO-25-00254"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00254","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500254"}}